Introduction to Allergyrhino
The Ventures Arm of a state broadcaster is involved in a new company for digital healthcare, aimed at combating chronic allergies in Great Britain. Allergyrhino, which provides patients with personalized allergy immunotherapy, has concluded a contract with the broadcaster’s ventures arm as part of a fundraiser. The fundraiser also includes an early investment company.
The Agreement
The media-for-equity arrangement gives Allergyrhino access to the broadcaster’s advertising stock, allowing the company to establish name recognition. This is the latest such agreement signed by the broadcaster’s ventures arm, with previous counterparts including an online real estate agent and a crowd-funding platform.
Founders and Clinical Consultants
Allergyrhino was founded by Dr. Sneh Khemka, a former global medical boss at a healthcare company and ex-boss at a health insurance provider. The company’s clinical consultants include Professor Adam Fox, former president of the British Society for Allergy and Clinical Immunology, and Professor Stephen Till, a consultant allergy specialist at a NHS Foundation Trust.
The Problem of Chronic Allergies
The formation of Allergyrhino comes as the problem of chronic allergies in Great Britain continues to grow. Data indicates that every fourth person now lives with seasonal or persistent rhinitis, triggered by factors such as hay fever and dust mite allergy. This is said to be the fastest growing chronic illness in children.
Financing Round
The financing round, which includes the value of the venture deal and capital from the broadcaster and the early investment company, is said to be worth more than £4 million. The broadcaster and the other parties involved have declined to comment on the deal.
